³»½Ã°æ ¿ªÇà Ãé´ã°ü Á¶¿µ¼ú(ERCP) ½ÃÀå º¸°í¼­ : µ¿Çâ, ¿¹Ãø, °æÀï ºÐ¼®(-2030³â)
Endoscopic Retrograde Cholangiopancreatography Market Report: Trends, Forecast and Competitive Analysis to 2030
»óǰÄÚµå : 1417393
¸®¼­Ä¡»ç : Lucintel
¹ßÇàÀÏ : 2024³â 01¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 150 - page report
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,850 £Ü 6,850,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. PDF ÆÄÀÏÀº DRM(µðÁöÅÐ ÀúÀÛ±Ç °ü¸® ½Ã½ºÅÛ)ÀÌ ÀåÂøµÇ¾î ÀÖ½À´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 5,800 £Ü 8,192,000
PDF (2 Users License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 2¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. PDF ÆÄÀÏÀº DRM(µðÁöÅÐ ÀúÀÛ±Ç °ü¸® ½Ã½ºÅÛ)ÀÌ ÀåÂøµÇ¾î ÀÖ½À´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,700 £Ü 9,463,000
PDF (5 Users License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. PDF ÆÄÀÏÀº DRM(µðÁöÅÐ ÀúÀÛ±Ç °ü¸® ½Ã½ºÅÛ)ÀÌ ÀåÂøµÇ¾î ÀÖ½À´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,850 £Ü 12,500,000
PDF (Corporate License) help
PDF º¸°í¼­¸¦ ±â¾÷ ³» ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÀÌ¿ë Àοø¿¡ Á¦ÇÑÀº ¾øÀ¸³ª, ±¹³»¿¡ ÀÖ´Â »ç¾÷À常 ÇØ´çµÇ¸ç, ÇØ¿Ü ÁöÁ¡ µîÀº Æ÷ÇÔµÇÁö ¾Ê½À´Ï´Ù. PDF ÆÄÀÏÀº DRM(µðÁöÅÐ ÀúÀÛ±Ç °ü¸® ½Ã½ºÅÛ)ÀÌ ÀåÂøµÇ¾î ÀÖ½À´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¤± º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼Û±âÀÏÀº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

³»½Ã°æ ¿ªÇà Ãé´ã°ü Á¶¿µ¼ú µ¿Çâ°ú ¿¹Ãø

¼¼°èÀÇ ³»½Ã°æ ¿ªÇà Ãé´ã°ü Á¶¿µ¼ú ½ÃÀå ±Ô¸ð´Â 2024³âºÎÅÍ 2030³â±îÁö CAGR 5.5%·Î ¼ºÀåÇϰí, 2030³â±îÁö ¾à 19¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ ½ÃÀåÀÇ ÁÖ¿ä ¼ºÀå ÃËÁø¿äÀÎÀº ¾Ï ÀÌȯÀ² »ó½Â, ÃÖ¼Òħ½À ½Ã¼ú¡¤¼ö¼ú¿¡ ´ëÇÑ ÁöÇâ »ó½Â, Á¤ºÎ³ª ÇコÄÉ¾î ±â°ü¿¡¼­ ÀçÁ¤Àû Ä¿¹ÌÆ®¸ÕÆ® »ó½ÂÀÔ´Ï´Ù. ¼¼°èÀÇ ³»½Ã°æ ¿ªÇà Ãé´ã°ü Á¶¿µ¼ú ½ÃÀåÀÇ ¹Ì·¡´Â º´¿øÀ̳ª ¿Ü·¡ ¼ö¼ú ¼¾ÅÍ¡¤Å¬¸®´Ð ½ÃÀå¿¡¼­ÀÇ ±âȸ·Î À¯¸ÁÇØ º¸ÀÔ´Ï´Ù.

³»½Ã°æ ¿ªÇà Ãé´ã°ü Á¶¿µ¼ú ½ÃÀå ÀλçÀÌÆ®

LucintelÀº ¼ÒÈ­±âÁúȯ ÀÌȯÀ² Áõ°¡¿¡ ÀÇÇØ ¿¹Ãø±â°£ Áß ³»½Ã°æ Ä¡·á Àåºñ°¡ ÃÖ´ë ºÎ¹®À¸·Î ³²À» °ÍÀ¸·Î ¿¹ÃøÇϰí ÀÖ½À´Ï´Ù.

ÀÌ ½ÃÀå Áß¿¡¼­ º´¿øÀº ÀÌ·¯ÇÑ ½Ã¼³¿¡¼­ Æø³ÐÀº ERCP µð¹ÙÀ̽º¸¦ ÀÌ¿ëÇÒ ¼ö Àֱ⠶§¹®¿¡ ÃÖ´ë ºÎ¹®À¸·Î ³²À» °ÍÀ¸·Î »ý°¢µË´Ï´Ù.

ºÏ¹Ì´Â ¾Ï ȯÀÚ Áõ°¡¿Í ÷´Ü ERCP Åø µµÀÔÀ¸·Î ¿¹Ãø±â°£ µ¿¾È ÃÖ´ë Áö¿ªÀ¸·Î ³²À» °ÍÀ¸·Î »ý°¢µË´Ï´Ù.

ÀÚÁÖ ¹¯´Â Áú¹®

Q1. ½ÃÀå ±Ô¸ð´Â?

A1. ¼¼°èÀÇ ³»½Ã°æ ¿ªÇà Ãé´ã°ü Á¶¿µ¼ú ½ÃÀåÀº 2030³â±îÁö ¾à 19¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

Q2. ½ÃÀå ¼ºÀå ¿¹ÃøÀº?

A2. ¼¼°èÀÇ ³»½Ã°æ ¿ªÇà Ãé´ã°ü Á¶¿µ¼ú ½ÃÀåÀº 2024³âºÎÅÍ 2030³â±îÁö CAGR 5.5%·Î ¼ºÀåÇÒ Àü¸ÁÀÔ´Ï´Ù.

Q3. ½ÃÀåÀÇ ¼ºÀå¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â ÁÖ¿ä ¼ºÀå ÃËÁø¿äÀÎÀº?

A3. ÀÌ ½ÃÀåÀÇ ÁÖ¿ä ¼ºÀå ÃËÁø¿äÀÎÀº ¾Ï ÀÌȯÀ² »ó½Â, ÃÖ¼Òħ½À ½Ã¼ú¡¤¼ö¼ú¿¡ ´ëÇÑ ÁöÇâ »ó½Â, Á¤ºÎ³ª ÇコÄÉ¾î ±â°ü¿¡¼­ ÀçÁ¤Àû Ä¿¹ÌÆ®¸ÕÆ® Áõ´ëÀÔ´Ï´Ù.

Q4. ½ÃÀåÀÇ ÁÖ¿ä ºÎ¹®Àº?

A4. ³»½Ã°æ ¿ªÇà Ãé´ã°ü Á¶¿µ¼ú ½ÃÀåÀÇ ¹Ì·¡´Â º´¿ø ¹× ¿Ü·¡ ¼ö¼ú ¼¾ÅÍ¡¤Å¬¸®´Ð ½ÃÀå¿¡¼­ÀÇ ±âȸ¿¡ ÀÇÇØ À¯¸Á½Ã µË´Ï´Ù.

Q5. ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷Àº?

A5. ³»½Ã°æ ¿ªÇà Ãé´ã°ü Á¶¿µ¼úÀÇ ÁÖ¿ä ±â¾÷Àº ´ÙÀ½°ú °°½À´Ï´Ù.

Q6. ÇâÈÄ ÃÖ´ë°¡ µÇ´Â ½ÃÀå ºÎ¹®Àº?

A6. LucintelÀº ¼ÒÈ­±âÁúȯ ÀÌȯÀ² Áõ°¡¿¡ ÀÇÇØ ¿¹Ãø±â°£ Áß ³»½Ã°æ Ä¡·á Àåºñ°¡ ÃÖ´ë ºÎ¹®À¸·Î ³²À» °ÍÀ¸·Î ¿¹ÃøÇϰí ÀÖ½À´Ï´Ù.

Q7. ½ÃÀå¿¡¼­ ÇâÈÄ 5³â µ¿¾È ÃÖ´ë°¡ µÉ °ÍÀ¸·Î ¿¹»óµÇ´Â Áö¿ªÀº?

A7. ºÏ¹Ì´Â ¾Ï ȯÀÚ Áõ°¡¿Í ÷´Ü ERCP Åø µµÀÔÀ¸·Î ¿¹Ãø±â°£ Áß¿¡µµ ÃÖ´ë Áö¿ªÀ¸·Î ³²À» °ÍÀÔ´Ï´Ù.

Q8. º¸°í¼­ Ä¿½ºÅ͸¶ÀÌ¡ÀÌ °¡´É?

A8. ³×, LucintelÀº Ãß°¡ ºñ¿ë ¾øÀÌ 10% Ä¿½ºÅ͸¶ÀÌ¡À» Á¦°øÇÕ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ¼¼°èÀÇ ³»½Ã°æ ¿ªÇà Ãé´ã°ü Á¶¿µ¼ú ½ÃÀå : ½ÃÀå ¿ªÇÐ

Á¦3Àå ½ÃÀå µ¿Çâ°ú ¿¹Ãø ºÐ¼®(2018-2030³â)

Á¦4Àå ½ÃÀå µ¿Çâ°ú ¿¹Ãø ºÐ¼® : Áö¿ªº°(2018-2030³â)

Á¦5Àå °æÀï ºÐ¼®

Á¦6Àå ¼ºÀå ±âȸ¿Í Àü·«Àû ºÐ¼®

Á¦7Àå À¯·Â ±â¾÷ÀÇ ±â¾÷ °³¿ä

KSM
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Endoscopic Retrograde Cholangiopancreatography Trends and Forecast

The future of the global endoscopic retrograde cholangiopancreatography market looks promising with opportunities in the hospital and ambulatory surgery center & clinic markets. The global endoscopic retrograde cholangiopancreatography market is expected to reach an estimated $1.9 billion by 2030 with a CAGR of 5.5% from 2024 to 2030. The major drivers for this market are elevated cancer rates, increasing inclination towards minimally invasive procedures and surgeries, and growing financial commitments from governments and healthcare institutions.

A more than 150-page report is developed to help in your business decisions.

Endoscopic Retrograde Cholangiopancreatography by Segment

The study includes a forecast for the global endoscopic retrograde cholangiopancreatography by product, procedure, end use, and region.

Endoscopic Retrograde Cholangiopancreatography Market by Product [Shipment Analysis by Value from 2018 to 2030]:

Endoscopic Retrograde Cholangiopancreatography Market by Procedure [Shipment Analysis by Value from 2018 to 2030]:

Endoscopic Retrograde Cholangiopancreatography Market by End Use [Shipment Analysis by Value from 2018 to 2030]:

Endoscopic Retrograde Cholangiopancreatography Market by Region [Shipment Analysis by Value from 2018 to 2030]:

List of Endoscopic Retrograde Cholangiopancreatography Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies endoscopic retrograde cholangiopancreatography companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the endoscopic retrograde cholangiopancreatography companies profiled in this report include-

Endoscopic Retrograde Cholangiopancreatography Market Insights

Lucintel forecasts that endotherapy device will remain the largest segment over the forecast period due to growing incidence of gastrointestinal disorders.

Within this market, hospital will remain the largest segment due to availability of wide range of ERCP devices in these facilities.

North America will remain the largest region over the forecast period due to rising frequency of cancer cases and introduction of advanced ERCP tools in the region.

Features of the Global Endoscopic Retrograde Cholangiopancreatography Market

Market Size Estimates: Endoscopic retrograde cholangiopancreatography market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Endoscopic retrograde cholangiopancreatography market size by product, procedure, end use, and region in terms of value ($B).

Regional Analysis: Endoscopic retrograde cholangiopancreatography market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different products, procedures, end uses, and regions for the endoscopic retrograde cholangiopancreatography market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the endoscopic retrograde cholangiopancreatography market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the endoscopic retrograde cholangiopancreatography market size?

Answer: The global endoscopic retrograde cholangiopancreatography market is expected to reach an estimated $1.9 billion by 2030.

Q2. What is the growth forecast for endoscopic retrograde cholangiopancreatography market?

Answer: The global endoscopic retrograde cholangiopancreatography market is expected to grow with a CAGR of 5.5% from 2024 to 2030.

Q3. What are the major drivers influencing the growth of the endoscopic retrograde cholangiopancreatography market?

Answer: The major drivers for this market are elevated cancer rates, increasing inclination towards minimally invasive procedures and surgeries, and growing financial commitments from governments and healthcare institutions.

Q4. What are the major segments for endoscopic retrograde cholangiopancreatography market?

Answer: The future of the endoscopic retrograde cholangiopancreatography market looks promising with opportunities in the hospital and ambulatory surgery center & clinic markets.

Q5. Who are the key endoscopic retrograde cholangiopancreatography market companies?

Answer: Some of the key endoscopic retrograde cholangiopancreatography companies are as follows.

Q6. Which endoscopic retrograde cholangiopancreatography market segment will be the largest in future?

Answer: Lucintel forecasts that endotherapy device will remain the largest segment over the forecast period due to growing incidence of gastrointestinal disorders.

Q7. In endoscopic retrograde cholangiopancreatography market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region over the forecast period due to rising frequency of cancer cases and introduction of advanced ERCP tools in the region.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

Table of Contents

1. Executive Summary

2. Global Endoscopic Retrograde Cholangiopancreatography Market : Market Dynamics

3. Market Trends and Forecast Analysis from 2018 to 2030

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

5. Competitor Analysis

6. Growth Opportunities and Strategic Analysis

7. Company Profiles of Leading Players

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â